n a boost for Sarepta Therapeutics (SRPT), the last remaining large health insurer has agreed to cover its pricey treatment for a rare form of muscular dystrophy.

In a policy bulletin issued on Thursday, Anthem (ANTM) declared Exondys 51 to be “medically necessary,” reversing a decision made a year ago not to reimburse the drug, which had just been approved to treat Duchenne muscular dystrophy amid controversy about underlying clinical data.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • My son Shivam Anjay age 19 years patient of DMD needs treatment by sarepta Exondys 51, when this medicine will be available in India or if I want to get treatment at USA what cost I have to bear, pl help and guide me.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.